American College of Cardiology/American Heart Association 2016 dual antiplatelet therapy (DAPT) focused update: Implications for surgeons

Journal of Thoracic and Cardiovascular Surgery

Volumn 152, Issue 5, 2016, Pages 1276-1278

  Shemin, Richard J ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR; 2'-DEOXYTHYMIDYLYL-(3'-5')-2'-DEOXYADENOSINE; ANTITHROMBOCYTIC AGENT; DINUCLEOSIDE PHOSPHATE;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIAC SURGEON; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DUAL ANTIPLATELET THERAPY; EDITORIAL; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURGEON; CARDIOLOGY; UNITED STATES;

AMERICAN HEART ASSOCIATION; CARDIOLOGY; DINUCLEOSIDE PHOSPHATES; PLATELET AGGREGATION INHIBITORS; SURGEONS; UNITED STATES;

EID: 84967334525     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2016.04.047     Document Type: Editorial

References (34)

1. 1 Levine, G.N., Bates, E.R., Blankenship, J.C., Bailey, S.R., Bittl, J.A., Cercek, B., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
2. 2 Hillis, L.D., Smith, P.K., Anderson, J.L., Bittl, J.A., Bridges, C.R., Byrne, J.G., et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with The American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 58 (2011), e123–e210.
3. 3 Fihn, S.D., Blankenship, J.C., Alexander, K.P., Bittl, J.A., Byrne, J.G., Fletcher, B.J., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and The American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 64 (2015), 1929–1949.
4. 4 Fihn, S.D., Gardin, J.M., Abrams, J., Berra, K., Blankenship, J.C., Dallas, A.P., et al. 2012 CCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60 (2012), e44–e164.
5. 5 O'Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Chung, M.K., de Lemos, J.A., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), e78–e140.
6. 6 Amsterdam, E.A., Wenger, N.K., Brindis, R.G., Casey, D.E., Ganiats, T.G., Holmes, D.R., et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
7. 7 Fleisher, L.A., Fleischmann, K.E., Auerbach, A.D., Barnaso, S.A., Beckman, J.A., Bozkurt, B., et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e77–e137.
8. 8 Colombo, A., Chieffo, A., Frasheri, A., Garbo, R., Massotti-Centol, M., Salvatella, N., et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2397.
9. 9 Feres, F., Costa, R.A., Abizaid, A., Leon, M.B., Marin-Neto, J.A., Botelho, R.V., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
10. 10 Gilard, M., Barragan, P., Noryani, A.A., Noor, H.A., Majwal, T., Hovasse, T., et al. Six- versus 24-month dual antiplatelet therapy after implantation of drug- eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 65 (2015), 777–786.
11. 11 Gwon, H.C., Hahn, J.Y., Park, K.W., Song, Y.B., Chae, I.H., Lim, D.S, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
12. 12 Helft, G., Steg, P.G., Le, F.C., Le Feuvre, C., Georges, J.L., Carrie, D., et al. Stopping or continuing clopidogrel months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 37 (2015), 365–374.
13. 13 Kim, B.K., Hong, M.K., Shin, D.H., Nam, C.M., Kim, J.S., Ko, Y.G., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
14. 14 Lee, C.W., Ahn, J.M., Park, D.W., Kang, S.J., Lee, S.W., Kim, Y.H., et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 129 (2014), 304–312.
15. 15 Mauri, L., Kereiakes, D.J., Yeh, R.W., Driscoll-Shempp, P., Cutlip, D.E., Steg, G., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
16. 16 Park, S.J., Park, D.W., Kim, Y.H., Kang, S.J., Lee, S.W., Lee, C.W., et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362 (2010), 1374–1382.
17. 17 Schülz-Schüpke, S., Byrne, R.A., ten Berg, J.M., Neumann, F.J., Han, Y., Adriaenssens, T., et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 36 (2015), 1252–1263.
18. 18 Valgimigli, M., Campo, G., Monti, M., Vranckx, P., Percoco, G., Tumscitz, C., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
19. 19 Collet, J.P., Silvain, J., Barthelemy, O., Range, G., Cayla, G., Van Belle, E., et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384 (2014), 1577–1585.
20. 20 Bonaca, M.P., Bhatt, D.L., Cohen, M., Steg, P.G., Storey, R.F., Jensen, E.C., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
21. 21 Roffi, M., Patrono, C., Collet, J.P., Mueller, C., Valgimigli, M., Andreotti, F., et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 32 (2015), 2999–3054.
22. 22 Chesebro, J.H., Clements, I.P., Fuster, V., Elveback, L.R., Smith, H.C., Bardsley, W.T., et al. A platelet-inhibitor drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 307 (1982), 73–78.
23. 23 Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
24. 24 Fox, K.A., Mehta, S.R., Peters, R., Zhao, F., Lakkis, N., Gersh, B.J., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non–ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 (2004), 1202–1208.
25. 25 Ebrahimi, R., Bakaeen, F.G., Uberoi, A., Ardehali, A., Baltz, J.H., Hattler, B., et al. Effect of clopidogrel use post-coronary artery bypass surgery on graft patency. Ann Thorac Surg 97 (2014), 15–21.
26. 26 Kulik, A., Le May, M.R., Voisine, P., Tardif, J.C., Delarochelliere, R., Naidoo, S., et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial. Circulation 122 (2010), 2680–2687.
27. 27 Gao, C., Ren, C., Li, D., Li, L., Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. Ann Thorac Surg 88 (2009), 59–62.
28. 28 Sun, J.C., Teoh, K.H., Lamy, A., Sheth, T., Ellins, M.L., Jung, H., et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting Study. Am Heart J 160 (2010), 1178–1184.
29. 29 Gao, G., Zheng, Z., Pi, Y., Lu, B., Lu, J., Hu, S., et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 56 (2010), 1639–1643.
30. 30 Deo, S.V., Dunlay, S.M., Shah, I.K., Altarabsheh, S.E., Erwin, P.J., Boilson, B.A., et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg 28 (2013), 109–116.
31. 31 Nocerino, A.G., Achenbach, S., Taylor, A.J., Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol 112 (2013), 1576–1579.
32. 32 de Leon, N., Jackevicius, C.A., Use of aspirin and clopidogrel after coronary artery bypass graft surgery. Ann Pharmacother 46 (2012), 678–687.
33. 33 Ibrahim, K., Tjomsland, O., Halvorsen, D., Wiseth, R., Wahba, A., Karevold, A., et al. Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery. Heart Surg Forum 9 (2006), E581–E856.
34. 34 Mannacio, V.A., Di Tommasco, L., De Amicis, V., Antignan, A., Vosa, C., Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypass occlusion After off-pump procedures) randomised study. Heart 98 (2012), 1710–1715.